Nov 20, 2017 15:50 JST

Source: Eisai

Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN
Equipped with Functions to Support Looking After Patients

TOKYO, Nov 20, 2017 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received an "IT Business Award" for its medication administration support device e-OKUSURI-SAN at the fiscal 2017 (35th) IT Awards held by the Japan Institute of Information Technology (JiIT).

Front of e-OKUSURI-SAN
 


http://www.acnnewswire.com/topimg/Low_FronteOKUSURISAN.jpg
Front of e-OKUSURI-SAN

The IT Awards are given to companies, organizations, other bodies and individuals in recognition of results from notable efforts made in "business innovation through high-level use of IT" by the JiIT, whose designated aim is to promote improvements in productivity in the activities of Japanese industry and government bodies as well as implementation of effective management systems. The "IT Business Award" received by Eisai was awarded based on the verification of notable results in realizing a strategic advantage as well as contributing to management via expansion and creation of business through the effective implementation and use of IT in business activities.

e-OKUSURI-SAN supports treatment administration for patients, families, pharmacists, nurses and caregivers, by ensuring that the prescribed dosage of medicine is administered at the scheduled time, thus helping to prevent patients from forgetting to take medicine or overdosing. The device is also equipped with a function to support looking after patients by allowing those concerned, including family and pharmacists, to remotely confirm a patient's record of medicine administration via an exclusive cloud website system.

In the demonstration experiments conducted ahead of the launch of e-OKUSURI-SAN as well as hearings post-launch, various benefits were observed, including an increase in administration rates, contribution to prevention of overdosing, a reduction in the burden on families, pharmacists, nurses and caregivers to support patients, and an enhancement in interprofessional collaboration through the provision of administration information.

In the selection for this award, the results of the new value provided by e-OKUSURI-SAN to home care patients as well as families and medical and nursing care professionals supporting the rehabilitation activities of patients were assessed, and selected for the "IT Business Award."

Eisai has been engaged for many years in activities for "creating communities where people can live with peace of mind." In carrying out these activities, Eisai has identified real world needs and issues. By providing solutions to these needs and issues in cooperation with stakeholders including local governments, medical institutions and pharmacies, Eisai seeks to make continued contributions to address the diverse needs of, as well as increasing the benefits provided to, patients and their families.

About e-OKUSURI-SAN

Up to four doses can be scheduled per day (morning, middle of the day, night, before bed), with a week's worth of medicine able to be set in the device. At the scheduled time, a tray with a medicine case slides out, with simultaneous audio and visual prompts. If the case has not been taken from the tray, the snooze function can be used to replay the audio prompts. If 40 minutes have passed without the medicine case being taken from the tray, the medicine case will be automatically retracted into the device. As a general rule, medicine cases cannot be retrieved until the next scheduled administration time to prevent patients from overdosing. Information on medicine administration is encrypted and managed individually on an exclusive website on the cloud. It is possible to have an email sent to registered individuals such as family members or pharmacists whenever a medicine case has been taken or if a medicine case was retracted without being taken.

Monthly data can be viewed as a line graph or table, making it easy to see if a patient is regularly following administration times or not. Eisai Co., Ltd. markets e-OKUSURI-SAN in Japan mainly through pharmacies, medical institutions and care facilities. For inquiries relating to the device, please visit: http://e-okusurisan.com (available in Japanese only)

* e-OKUSURI-SAN is not a medical device.

About the Japan Institute of Information Technology

The Japan Institute of Information Technology (JiIT) was established in 1981 as an "organ for the promotion of management innovation through the utilization of IT." Conducting survey research and development into the digitalization of companies and encouraging the spread and implementation of the results, the JiIT aims to contribute the healthy development of Japanese society, economy and industry. Working to select themes in accordance with the needs of the times and expand its activities, the JiIT is pushing forward with the sound digitalization of both industries and companies.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
 
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
 
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
 
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
 
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
 
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
 
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
 
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
 
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
 
More Press release >>

Latest Press Release


More Latest Release >>